サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1395763

重症筋無力症治療の世界市場規模、シェア、産業動向分析レポート：最終用途別、タイプ別、地域別展望と予測、2023年～2030年

Global Myasthenia Gravis Treatment Market Size, Share & Industry Trends Analysis Report By End-use (Hospitals, Clinics and Others), By Type, By Regional Outlook and Forecast, 2023 - 2030
出版日: | 発行: KBV Research | ページ情報: 英文 216 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
重症筋無力症治療の世界市場規模、シェア、産業動向分析レポート：最終用途別、タイプ別、地域別展望と予測、2023年～2030年
出版日: 2023年11月30日
発行: KBV Research
ページ情報: 英文 216 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

重症筋無力症治療市場規模は、予測期間中にCAGR 9.2％で成長し、2030年までに38億米ドルに達すると予測されます。

しかし、重症筋無力症はその不均一性で知られており、症状、重症度、治療反応が個人間で大きく異なる可能性があります。ある患者には効果があっても、別の患者には効果がないこともあります。このため、普遍的に有効な治療法を見つけることは困難です。重症筋無力症の症状を管理するために一般的に使用される薬剤の多くは、様々な副作用を引き起こす可能性があります。これらの要因が市場の成長を妨げると予想されます。

さらに、重症筋無力症のような慢性疾患を持つ多くの人々が、パンデミックのピーク時には、医療システムの過密化、リソースの再配分、不要不急のサービスの制限により、日常的なヘルスケアサービスの中断に直面しました。対面診療が制限されたことで、神経科医やその他のMGの専門家による専門的な治療へのアクセスが制限され、疾病管理や個別の治療計画に影響を与えました。処方された薬が入手できなかったり、遅れたりしたため、治療が中断され、MGの症状のコントロールに影響を与える可能性があっています。必要な薬剤の入手が不十分であったため、疾患の増悪や再燃が起こり、筋力低下、疲労、その他MGに関連する症状が増加しました。したがって、COVID-19の大流行は重症筋無力症治療薬市場にマイナスの影響を与えました。

最終用途別の展望

最終用途に基づき、市場は病院、診療所、その他に分けられます。2022年には、診療所セグメントが市場で大きな売上シェアを占めました。重症筋無力症を含む神経筋疾患に特化したクリニックでは、神経内科医、免疫学者、その他この疾患の管理に精通した専門家による包括的な治療が提供されます。専門的なケアに対する需要が、こうしたクリニックの成長を促進する可能性があります。

タイプ別展望

タイプ別に見ると、市場はコリンエステラーゼ阻害薬、慢性免疫調節薬、モノクローナル抗体、迅速免疫療法、胸腺摘出術、その他に区分されます。モノクローナル抗体セグメントは、2022年の市場において最大の収益シェアを記録しました。モノクローナル抗体は、重症筋無力症の病因に関与していると疑われる特定の免疫系成分を標的とする生物学的療法の一種です。

地域別展望

地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAに区分されます。北米セグメントは、2022年の市場で最も高い収益シェアを獲得しました。北米では重症筋無力症の有病率がかなり高いです。診断能力の向上とヘルスケア専門家の意識の高まりにより、重症筋無力症の診断がより正確かつタイムリーに行われるようになり、治療に対する需要が高まっています。

目次

第1章 市場範囲と調査手法

  • 市場の定義
  • 目的
  • 市場範囲
  • セグメンテーション
  • 調査手法

第2章 市場要覧

  • 主なハイライト

第3章 市場概要

  • イントロダクション
    • 概要
      • 市場構成とシナリオ
  • 市場に影響を与える主な要因
    • 市場促進要因
    • 市場抑制要因
  • ポーターファイブフォース分析

第4章 世界の重症筋無力症治療市場：最終用途別

  • 世界の病院市場：地域別
  • 世界のクリニック市場：地域別
  • 世界のその他の市場：地域別

第5章 世界の重症筋無力症治療市場：タイプ別

  • 世界のモノクローナル抗体市場：地域別
  • 世界の胸腺摘出市場：地域別
  • 世界のコリンエステラーゼ阻害剤市場：地域別
  • 世界の慢性免疫調節剤市場：地域別
  • 世界の迅速免疫療法市場：地域別
  • 世界のその他の市場：地域別

第6章 世界の重症筋無力症治療市場：地域別

  • 北米
    • 北米の市場：国別
      • 米国
      • カナダ
      • メキシコ
      • その他北米地域
  • 欧州
    • 欧州の市場：国別
      • ドイツ
      • 英国
      • フランス
      • ロシア
      • スペイン
      • イタリア
      • その他欧州地域
  • アジア太平洋
    • アジア太平洋の市場：国別
      • 中国
      • 日本
      • インド
      • 韓国
      • シンガポール
      • マレーシア
      • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ラテンアメリカ・中東・アフリカの市場：国別
      • ブラジル
      • アルゼンチン
      • アラブ首長国連邦
      • サウジアラビア
      • 南アフリカ
      • ナイジェリア
      • その他ラテンアメリカ・中東・アフリカ地域

第7章 企業プロファイル

  • AstraZeneca PLC（Alexion Pharmaceuticals, Inc）
  • Octapharma AG
  • Novartis AG
  • Pfizer, Inc
  • Allergan PLC（AbbVie, Inc）
  • F Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC（GSK）
  • Bausch Health Companies Inc
  • Kedrion Sp.A
  • Zydus Lifesciences Ltd

第8章 市場の成功必須事項

図表

LIST OF TABLES

  • TABLE 1 Global Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 2 Global Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 3 Global Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 4 Global Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 5 Global Hospitals Market by Region, 2019 - 2022, USD Million
  • TABLE 6 Global Hospitals Market by Region, 2023 - 2030, USD Million
  • TABLE 7 Global Clinics Market by Region, 2019 - 2022, USD Million
  • TABLE 8 Global Clinics Market by Region, 2023 - 2030, USD Million
  • TABLE 9 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 10 Global Others Market by Region, 2023 - 2030, USD Million
  • TABLE 11 Global Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 12 Global Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 13 Global Monoclonal Antibodies Market by Region, 2019 - 2022, USD Million
  • TABLE 14 Global Monoclonal Antibodies Market by Region, 2023 - 2030, USD Million
  • TABLE 15 Global Thymectomy Market by Region, 2019 - 2022, USD Million
  • TABLE 16 Global Thymectomy Market by Region, 2023 - 2030, USD Million
  • TABLE 17 Global Cholinesterase Inhibitors Market by Region, 2019 - 2022, USD Million
  • TABLE 18 Global Cholinesterase Inhibitors Market by Region, 2023 - 2030, USD Million
  • TABLE 19 Global Chronic Immunomodulators Market by Region, 2019 - 2022, USD Million
  • TABLE 20 Global Chronic Immunomodulators Market by Region, 2023 - 2030, USD Million
  • TABLE 21 Global Rapid Immunotherapies Market by Region, 2019 - 2022, USD Million
  • TABLE 22 Global Rapid Immunotherapies Market by Region, 2023 - 2030, USD Million
  • TABLE 23 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 24 Global Others Market by Region, 2023 - 2030, USD Million
  • TABLE 25 Global Myasthenia Gravis Treatment Market by Region, 2019 - 2022, USD Million
  • TABLE 26 Global Myasthenia Gravis Treatment Market by Region, 2023 - 2030, USD Million
  • TABLE 27 North America Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 28 North America Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 29 North America Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 30 North America Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 31 North America Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 32 North America Hospitals Market by Country, 2023 - 2030, USD Million
  • TABLE 33 North America Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 34 North America Clinics Market by Country, 2023 - 2030, USD Million
  • TABLE 35 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 36 North America Others Market by Country, 2023 - 2030, USD Million
  • TABLE 37 North America Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 38 North America Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 39 North America Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
  • TABLE 40 North America Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
  • TABLE 41 North America Thymectomy Market by Country, 2019 - 2022, USD Million
  • TABLE 42 North America Thymectomy Market by Country, 2023 - 2030, USD Million
  • TABLE 43 North America Cholinesterase Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 44 North America Cholinesterase Inhibitors Market by Country, 2023 - 2030, USD Million
  • TABLE 45 North America Chronic Immunomodulators Market by Country, 2019 - 2022, USD Million
  • TABLE 46 North America Chronic Immunomodulators Market by Country, 2023 - 2030, USD Million
  • TABLE 47 North America Rapid Immunotherapies Market by Country, 2019 - 2022, USD Million
  • TABLE 48 North America Rapid Immunotherapies Market by Country, 2023 - 2030, USD Million
  • TABLE 49 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 50 North America Others Market by Country, 2023 - 2030, USD Million
  • TABLE 51 North America Myasthenia Gravis Treatment Market by Country, 2019 - 2022, USD Million
  • TABLE 52 North America Myasthenia Gravis Treatment Market by Country, 2023 - 2030, USD Million
  • TABLE 53 US Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 54 US Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 55 US Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 56 US Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 57 US Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 58 US Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 59 Canada Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 60 Canada Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 61 Canada Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 62 Canada Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 63 Canada Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 64 Canada Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 65 Mexico Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 66 Mexico Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 67 Mexico Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 68 Mexico Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 69 Mexico Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 70 Mexico Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 71 Rest of North America Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 72 Rest of North America Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 73 Rest of North America Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 74 Rest of North America Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 75 Rest of North America Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 76 Rest of North America Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 77 Europe Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 78 Europe Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 79 Europe Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 80 Europe Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 81 Europe Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 82 Europe Hospitals Market by Country, 2023 - 2030, USD Million
  • TABLE 83 Europe Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 84 Europe Clinics Market by Country, 2023 - 2030, USD Million
  • TABLE 85 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 86 Europe Others Market by Country, 2023 - 2030, USD Million
  • TABLE 87 Europe Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 88 Europe Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 89 Europe Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
  • TABLE 90 Europe Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
  • TABLE 91 Europe Thymectomy Market by Country, 2019 - 2022, USD Million
  • TABLE 92 Europe Thymectomy Market by Country, 2023 - 2030, USD Million
  • TABLE 93 Europe Cholinesterase Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 94 Europe Cholinesterase Inhibitors Market by Country, 2023 - 2030, USD Million
  • TABLE 95 Europe Chronic Immunomodulators Market by Country, 2019 - 2022, USD Million
  • TABLE 96 Europe Chronic Immunomodulators Market by Country, 2023 - 2030, USD Million
  • TABLE 97 Europe Rapid Immunotherapies Market by Country, 2019 - 2022, USD Million
  • TABLE 98 Europe Rapid Immunotherapies Market by Country, 2023 - 2030, USD Million
  • TABLE 99 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 100 Europe Others Market by Country, 2023 - 2030, USD Million
  • TABLE 101 Europe Myasthenia Gravis Treatment Market by Country, 2019 - 2022, USD Million
  • TABLE 102 Europe Myasthenia Gravis Treatment Market by Country, 2023 - 2030, USD Million
  • TABLE 103 Germany Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 104 Germany Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 105 Germany Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 106 Germany Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 107 Germany Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 108 Germany Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 109 UK Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 110 UK Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 111 UK Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 112 UK Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 113 UK Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 114 UK Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 115 France Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 116 France Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 117 France Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 118 France Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 119 France Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 120 France Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 121 Russia Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 122 Russia Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 123 Russia Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 124 Russia Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 125 Russia Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 126 Russia Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 127 Spain Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 128 Spain Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 129 Spain Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 130 Spain Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 131 Spain Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 132 Spain Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 133 Italy Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 134 Italy Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 135 Italy Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 136 Italy Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 137 Italy Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 138 Italy Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 139 Rest of Europe Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 140 Rest of Europe Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 141 Rest of Europe Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 142 Rest of Europe Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 143 Rest of Europe Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 144 Rest of Europe Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 145 Asia Pacific Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 146 Asia Pacific Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 147 Asia Pacific Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 148 Asia Pacific Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 149 Asia Pacific Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 150 Asia Pacific Hospitals Market by Country, 2023 - 2030, USD Million
  • TABLE 151 Asia Pacific Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 152 Asia Pacific Clinics Market by Country, 2023 - 2030, USD Million
  • TABLE 153 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 154 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
  • TABLE 155 Asia Pacific Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 156 Asia Pacific Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 157 Asia Pacific Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
  • TABLE 158 Asia Pacific Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
  • TABLE 159 Asia Pacific Thymectomy Market by Country, 2019 - 2022, USD Million
  • TABLE 160 Asia Pacific Thymectomy Market by Country, 2023 - 2030, USD Million
  • TABLE 161 Asia Pacific Cholinesterase Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 162 Asia Pacific Cholinesterase Inhibitors Market by Country, 2023 - 2030, USD Million
  • TABLE 163 Asia Pacific Chronic Immunomodulators Market by Country, 2019 - 2022, USD Million
  • TABLE 164 Asia Pacific Chronic Immunomodulators Market by Country, 2023 - 2030, USD Million
  • TABLE 165 Asia Pacific Rapid Immunotherapies Market by Country, 2019 - 2022, USD Million
  • TABLE 166 Asia Pacific Rapid Immunotherapies Market by Country, 2023 - 2030, USD Million
  • TABLE 167 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 168 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
  • TABLE 169 Asia Pacific Myasthenia Gravis Treatment Market by Country, 2019 - 2022, USD Million
  • TABLE 170 Asia Pacific Myasthenia Gravis Treatment Market by Country, 2023 - 2030, USD Million
  • TABLE 171 China Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 172 China Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 173 China Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 174 China Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 175 China Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 176 China Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 177 Japan Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 178 Japan Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 179 Japan Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 180 Japan Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 181 Japan Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 182 Japan Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 183 India Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 184 India Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 185 India Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 186 India Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 187 India Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 188 India Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 189 South Korea Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 190 South Korea Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 191 South Korea Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 192 South Korea Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 193 South Korea Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 194 South Korea Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 195 Singapore Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 196 Singapore Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 197 Singapore Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 198 Singapore Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 199 Singapore Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 200 Singapore Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 201 Malaysia Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 202 Malaysia Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 203 Malaysia Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 204 Malaysia Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 205 Malaysia Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 206 Malaysia Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 207 Rest of Asia Pacific Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 208 Rest of Asia Pacific Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 209 Rest of Asia Pacific Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 210 Rest of Asia Pacific Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 211 Rest of Asia Pacific Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 212 Rest of Asia Pacific Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 213 LAMEA Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 214 LAMEA Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 215 LAMEA Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 216 LAMEA Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 217 LAMEA Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 218 LAMEA Hospitals Market by Country, 2023 - 2030, USD Million
  • TABLE 219 LAMEA Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 220 LAMEA Clinics Market by Country, 2023 - 2030, USD Million
  • TABLE 221 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 222 LAMEA Others Market by Country, 2023 - 2030, USD Million
  • TABLE 223 LAMEA Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 224 LAMEA Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 225 LAMEA Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
  • TABLE 226 LAMEA Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
  • TABLE 227 LAMEA Thymectomy Market by Country, 2019 - 2022, USD Million
  • TABLE 228 LAMEA Thymectomy Market by Country, 2023 - 2030, USD Million
  • TABLE 229 LAMEA Cholinesterase Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 230 LAMEA Cholinesterase Inhibitors Market by Country, 2023 - 2030, USD Million
  • TABLE 231 LAMEA Chronic Immunomodulators Market by Country, 2019 - 2022, USD Million
  • TABLE 232 LAMEA Chronic Immunomodulators Market by Country, 2023 - 2030, USD Million
  • TABLE 233 LAMEA Rapid Immunotherapies Market by Country, 2019 - 2022, USD Million
  • TABLE 234 LAMEA Rapid Immunotherapies Market by Country, 2023 - 2030, USD Million
  • TABLE 235 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 236 LAMEA Others Market by Country, 2023 - 2030, USD Million
  • TABLE 237 LAMEA Myasthenia Gravis Treatment Market by Country, 2019 - 2022, USD Million
  • TABLE 238 LAMEA Myasthenia Gravis Treatment Market by Country, 2023 - 2030, USD Million
  • TABLE 239 Brazil Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 240 Brazil Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 241 Brazil Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 242 Brazil Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 243 Brazil Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 244 Brazil Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 245 Argentina Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 246 Argentina Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 247 Argentina Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 248 Argentina Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 249 Argentina Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 250 Argentina Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 251 UAE Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 252 UAE Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 253 UAE Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 254 UAE Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 255 UAE Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 256 UAE Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 257 Saudi Arabia Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 258 Saudi Arabia Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 259 Saudi Arabia Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 260 Saudi Arabia Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 261 Saudi Arabia Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 262 Saudi Arabia Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 263 South Africa Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 264 South Africa Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 265 South Africa Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 266 South Africa Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 267 South Africa Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 268 South Africa Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 269 Nigeria Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 270 Nigeria Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 271 Nigeria Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 272 Nigeria Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 273 Nigeria Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 274 Nigeria Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 275 Rest of LAMEA Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
  • TABLE 276 Rest of LAMEA Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
  • TABLE 277 Rest of LAMEA Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
  • TABLE 278 Rest of LAMEA Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
  • TABLE 279 Rest of LAMEA Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
  • TABLE 280 Rest of LAMEA Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
  • TABLE 281 KEY INFORMATION - ASTRAZENECA PLC
  • TABLE 282 Key Information - Octapharma AG
  • TABLE 283 Key Information - Novartis AG
  • TABLE 284 Key Information - Pfizer, Inc.
  • TABLE 285 Key Information - Allergan PLC
  • TABLE 286 Key Information - F. Hoffmann-La Roche Ltd.
  • TABLE 287 Key Information - GlaxoSmithKline PLC
  • TABLE 288 Key Information - Bausch Health Companies Inc
  • TABLE 289 key Information - Kedrion S.p.A
  • TABLE 290 Key Information - Zydus Lifesciences Ltd.
目次

The Global Myasthenia Gravis Treatment Market size is expected to reach $3.8 billion by 2030, rising at a market growth of 9.2% CAGR during the forecast period.

Better awareness and improved diagnostic techniques led to more cases being identified, increasing the demand for myasthenia gravis treatments, including chronic immunomodulators. Therefore, chronic immunomodulators segment captured $127.2 million revenue in the market in 2022. Research into autoimmune diseases, including myasthenia gravis, has spurred the development of newer and more effective chronic immunomodulators. Companies invest in developing improved formulations or alternative medications with better efficacy and fewer side effects. Thus, due to these factors, the segment will witness increased demand in the coming years. Some of the factors impacting the market are increased awareness and diagnosis of myasthenia gravis, growing usage and development of biological drugs and targeted therapies, and lack of treatment options for myasthenia gravis.

Early diagnosis means more identified cases of myasthenia gravis. This expands the patient pool seeking treatment. As more patients are diagnosed early, there's a higher demand for treatments, medications, and therapies, potentially creating a larger opportunity for pharmaceutical companies and healthcare providers. Early intervention often means a more manageable disease course. Moreover, as more attention is drawn to the disease, regulatory bodies and funding agencies might show increased interest. This can result in expedited review processes, regulatory support, and potentially increased funding for research and development in the myasthenia gravis treatment space. Additionally, unlike more generalized immunosuppressive treatments, biologics and targeted therapies focus on specific components of the immune system responsible for the autoimmune response in myasthenia gravis. For instance, some drugs may target B cells, producing autoantibodies that attack the neuromuscular junction. Moreover, introducing biological drugs has spurred increased research and clinical trials focusing on these targeted therapies. This ongoing research contributes to an expanding knowledge base and potential for further advancements in treatment options for myasthenia gravis. These aspects will drive the expansion of the market.

However, myasthenia gravis is known for its heterogeneity, meaning the symptoms, severity, and treatment response can differ significantly among individuals. What works well for one patient might not be as effective for another. This makes it challenging to find a universally effective treatment. Many medications commonly used to manage myasthenia gravis symptoms can lead to various side effects. These factors are expected to hamper the growth of the market.

Additionally, many individuals with chronic conditions like MG faced disruptions in their routine healthcare services due to overwhelmed healthcare systems, reallocation of resources, and restrictions on non-essential services during the pandemic's peak. Restrictions on in-person consultations limited access to specialized care from neurologists and other MG specialists, impacting disease management and individualized treatment plans. The unavailability or delay in receiving prescribed medications led to interruptions in the treatment, potentially impacting the control of MG symptoms. Inadequate access to essential medications resulted in disease exacerbations or flares, leading to increased weakness, fatigue, and other symptoms associated with MG. Therefore, the COVID-19 pandemic had a negative impact on the myasthenia gravis treatment market.

End-Use Outlook

Based on end-use, the market is divided into hospitals, clinics, and others. In 2022, the clinics segment witnessed a substantial revenue share in the market. Clinics specifically dedicated to neuromuscular disorders, including myasthenia gravis, provide comprehensive care with neurologists, immunologists, and other specialists experienced in managing this condition. The demand for specialized care could fuel the growth of such clinics.

Type Outlook

On the basis of type, the market is segmented into cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy, and others. The monoclonal antibodies segment recorded the maximum revenue share in the market in 2022. Monoclonal antibodies are a type of biological therapy that targets certain immune system components suspected to be involved in the etiology of myasthenia gravis.

Regional Outlook

By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the market in 2022. North America has seen a considerable prevalence of myasthenia gravis. Better diagnostic capabilities and increased awareness among healthcare professionals have led to more accurate and timely diagnoses of the condition, driving the demand for treatments.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), Octapharma AG, Novartis AG, Pfizer, Inc., Allergan PLC (AbbVie, Inc.), F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Bausch Health Companies Inc., Kedrion S.p.A, and Zydus Lifesciences Ltd.

Scope of the Study

Market Segments covered in the Report:

By End-use

  • Hospitals
  • Clinics
  • Others

By Type

  • Monoclonal Antibodies
  • Thymectomy
  • Cholinesterase Inhibitors
  • Chronic Immunomodulators
  • Rapid Immunotherapies
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
  • Octapharma AG
  • Novartis AG
  • Pfizer, Inc.
  • Allergan PLC (AbbVie, Inc.)
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Bausch Health Companies Inc.
  • Kedrion S.p.A
  • Zydus Lifesciences Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Myasthenia Gravis Treatment Market, by End-use
    • 1.4.2 Global Myasthenia Gravis Treatment Market, by Type
    • 1.4.3 Global Myasthenia Gravis Treatment Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market at a Glance

  • 2.1 Key Highlights

Chapter 3. Market Overview

  • 3.1 Introduction
    • 3.1.1 Overview
      • 3.1.1.1 Market Composition and Scenario
  • 3.2 Key Factors Impacting the Market
    • 3.2.1 Market Drivers
    • 3.2.2 Market Restraints
  • 3.3 Porter Five Forces Analysis

Chapter 4. Global Myasthenia Gravis Treatment Market by End-use

  • 4.1 Global Hospitals Market by Region
  • 4.2 Global Clinics Market by Region
  • 4.3 Global Others Market by Region

Chapter 5. Global Myasthenia Gravis Treatment Market by Type

  • 5.1 Global Monoclonal Antibodies Market by Region
  • 5.2 Global Thymectomy Market by Region
  • 5.3 Global Cholinesterase Inhibitors Market by Region
  • 5.4 Global Chronic Immunomodulators Market by Region
  • 5.5 Global Rapid Immunotherapies Market by Region
  • 5.6 Global Others Market by Region

Chapter 6. Global Myasthenia Gravis Treatment Market by Region

  • 6.1 North America Myasthenia Gravis Treatment Market
    • 6.1.1 North America Myasthenia Gravis Treatment Market by End-use
      • 6.1.1.1 North America Hospitals Market by Country
      • 6.1.1.2 North America Clinics Market by Country
      • 6.1.1.3 North America Others Market by Country
    • 6.1.2 North America Myasthenia Gravis Treatment Market by Type
      • 6.1.2.1 North America Monoclonal Antibodies Market by Country
      • 6.1.2.2 North America Thymectomy Market by Country
      • 6.1.2.3 North America Cholinesterase Inhibitors Market by Country
      • 6.1.2.4 North America Chronic Immunomodulators Market by Country
      • 6.1.2.5 North America Rapid Immunotherapies Market by Country
      • 6.1.2.6 North America Others Market by Country
    • 6.1.3 North America Myasthenia Gravis Treatment Market by Country
      • 6.1.3.1 US Myasthenia Gravis Treatment Market
        • 6.1.3.1.1 US Myasthenia Gravis Treatment Market by End-use
        • 6.1.3.1.2 US Myasthenia Gravis Treatment Market by Type
      • 6.1.3.2 Canada Myasthenia Gravis Treatment Market
        • 6.1.3.2.1 Canada Myasthenia Gravis Treatment Market by End-use
        • 6.1.3.2.2 Canada Myasthenia Gravis Treatment Market by Type
      • 6.1.3.3 Mexico Myasthenia Gravis Treatment Market
        • 6.1.3.3.1 Mexico Myasthenia Gravis Treatment Market by End-use
        • 6.1.3.3.2 Mexico Myasthenia Gravis Treatment Market by Type
      • 6.1.3.4 Rest of North America Myasthenia Gravis Treatment Market
        • 6.1.3.4.1 Rest of North America Myasthenia Gravis Treatment Market by End-use
        • 6.1.3.4.2 Rest of North America Myasthenia Gravis Treatment Market by Type
  • 6.2 Europe Myasthenia Gravis Treatment Market
    • 6.2.1 Europe Myasthenia Gravis Treatment Market by End-use
      • 6.2.1.1 Europe Hospitals Market by Country
      • 6.2.1.2 Europe Clinics Market by Country
      • 6.2.1.3 Europe Others Market by Country
    • 6.2.2 Europe Myasthenia Gravis Treatment Market by Type
      • 6.2.2.1 Europe Monoclonal Antibodies Market by Country
      • 6.2.2.2 Europe Thymectomy Market by Country
      • 6.2.2.3 Europe Cholinesterase Inhibitors Market by Country
      • 6.2.2.4 Europe Chronic Immunomodulators Market by Country
      • 6.2.2.5 Europe Rapid Immunotherapies Market by Country
      • 6.2.2.6 Europe Others Market by Country
    • 6.2.3 Europe Myasthenia Gravis Treatment Market by Country
      • 6.2.3.1 Germany Myasthenia Gravis Treatment Market
        • 6.2.3.1.1 Germany Myasthenia Gravis Treatment Market by End-use
        • 6.2.3.1.2 Germany Myasthenia Gravis Treatment Market by Type
      • 6.2.3.2 UK Myasthenia Gravis Treatment Market
        • 6.2.3.2.1 UK Myasthenia Gravis Treatment Market by End-use
        • 6.2.3.2.2 UK Myasthenia Gravis Treatment Market by Type
      • 6.2.3.3 France Myasthenia Gravis Treatment Market
        • 6.2.3.3.1 France Myasthenia Gravis Treatment Market by End-use
        • 6.2.3.3.2 France Myasthenia Gravis Treatment Market by Type
      • 6.2.3.4 Russia Myasthenia Gravis Treatment Market
        • 6.2.3.4.1 Russia Myasthenia Gravis Treatment Market by End-use
        • 6.2.3.4.2 Russia Myasthenia Gravis Treatment Market by Type
      • 6.2.3.5 Spain Myasthenia Gravis Treatment Market
        • 6.2.3.5.1 Spain Myasthenia Gravis Treatment Market by End-use
        • 6.2.3.5.2 Spain Myasthenia Gravis Treatment Market by Type
      • 6.2.3.6 Italy Myasthenia Gravis Treatment Market
        • 6.2.3.6.1 Italy Myasthenia Gravis Treatment Market by End-use
        • 6.2.3.6.2 Italy Myasthenia Gravis Treatment Market by Type
      • 6.2.3.7 Rest of Europe Myasthenia Gravis Treatment Market
        • 6.2.3.7.1 Rest of Europe Myasthenia Gravis Treatment Market by End-use
        • 6.2.3.7.2 Rest of Europe Myasthenia Gravis Treatment Market by Type
  • 6.3 Asia Pacific Myasthenia Gravis Treatment Market
    • 6.3.1 Asia Pacific Myasthenia Gravis Treatment Market by End-use
      • 6.3.1.1 Asia Pacific Hospitals Market by Country
      • 6.3.1.2 Asia Pacific Clinics Market by Country
      • 6.3.1.3 Asia Pacific Others Market by Country
    • 6.3.2 Asia Pacific Myasthenia Gravis Treatment Market by Type
      • 6.3.2.1 Asia Pacific Monoclonal Antibodies Market by Country
      • 6.3.2.2 Asia Pacific Thymectomy Market by Country
      • 6.3.2.3 Asia Pacific Cholinesterase Inhibitors Market by Country
      • 6.3.2.4 Asia Pacific Chronic Immunomodulators Market by Country
      • 6.3.2.5 Asia Pacific Rapid Immunotherapies Market by Country
      • 6.3.2.6 Asia Pacific Others Market by Country
    • 6.3.3 Asia Pacific Myasthenia Gravis Treatment Market by Country
      • 6.3.3.1 China Myasthenia Gravis Treatment Market
        • 6.3.3.1.1 China Myasthenia Gravis Treatment Market by End-use
        • 6.3.3.1.2 China Myasthenia Gravis Treatment Market by Type
      • 6.3.3.2 Japan Myasthenia Gravis Treatment Market
        • 6.3.3.2.1 Japan Myasthenia Gravis Treatment Market by End-use
        • 6.3.3.2.2 Japan Myasthenia Gravis Treatment Market by Type
      • 6.3.3.3 India Myasthenia Gravis Treatment Market
        • 6.3.3.3.1 India Myasthenia Gravis Treatment Market by End-use
        • 6.3.3.3.2 India Myasthenia Gravis Treatment Market by Type
      • 6.3.3.4 South Korea Myasthenia Gravis Treatment Market
        • 6.3.3.4.1 South Korea Myasthenia Gravis Treatment Market by End-use
        • 6.3.3.4.2 South Korea Myasthenia Gravis Treatment Market by Type
      • 6.3.3.5 Singapore Myasthenia Gravis Treatment Market
        • 6.3.3.5.1 Singapore Myasthenia Gravis Treatment Market by End-use
        • 6.3.3.5.2 Singapore Myasthenia Gravis Treatment Market by Type
      • 6.3.3.6 Malaysia Myasthenia Gravis Treatment Market
        • 6.3.3.6.1 Malaysia Myasthenia Gravis Treatment Market by End-use
        • 6.3.3.6.2 Malaysia Myasthenia Gravis Treatment Market by Type
      • 6.3.3.7 Rest of Asia Pacific Myasthenia Gravis Treatment Market
        • 6.3.3.7.1 Rest of Asia Pacific Myasthenia Gravis Treatment Market by End-use
        • 6.3.3.7.2 Rest of Asia Pacific Myasthenia Gravis Treatment Market by Type
  • 6.4 LAMEA Myasthenia Gravis Treatment Market
    • 6.4.1 LAMEA Myasthenia Gravis Treatment Market by End-use
      • 6.4.1.1 LAMEA Hospitals Market by Country
      • 6.4.1.2 LAMEA Clinics Market by Country
      • 6.4.1.3 LAMEA Others Market by Country
    • 6.4.2 LAMEA Myasthenia Gravis Treatment Market by Type
      • 6.4.2.1 LAMEA Monoclonal Antibodies Market by Country
      • 6.4.2.2 LAMEA Thymectomy Market by Country
      • 6.4.2.3 LAMEA Cholinesterase Inhibitors Market by Country
      • 6.4.2.4 LAMEA Chronic Immunomodulators Market by Country
      • 6.4.2.5 LAMEA Rapid Immunotherapies Market by Country
      • 6.4.2.6 LAMEA Others Market by Country
    • 6.4.3 LAMEA Myasthenia Gravis Treatment Market by Country
      • 6.4.3.1 Brazil Myasthenia Gravis Treatment Market
        • 6.4.3.1.1 Brazil Myasthenia Gravis Treatment Market by End-use
        • 6.4.3.1.2 Brazil Myasthenia Gravis Treatment Market by Type
      • 6.4.3.2 Argentina Myasthenia Gravis Treatment Market
        • 6.4.3.2.1 Argentina Myasthenia Gravis Treatment Market by End-use
        • 6.4.3.2.2 Argentina Myasthenia Gravis Treatment Market by Type
      • 6.4.3.3 UAE Myasthenia Gravis Treatment Market
        • 6.4.3.3.1 UAE Myasthenia Gravis Treatment Market by End-use
        • 6.4.3.3.2 UAE Myasthenia Gravis Treatment Market by Type
      • 6.4.3.4 Saudi Arabia Myasthenia Gravis Treatment Market
        • 6.4.3.4.1 Saudi Arabia Myasthenia Gravis Treatment Market by End-use
        • 6.4.3.4.2 Saudi Arabia Myasthenia Gravis Treatment Market by Type
      • 6.4.3.5 South Africa Myasthenia Gravis Treatment Market
        • 6.4.3.5.1 South Africa Myasthenia Gravis Treatment Market by End-use
        • 6.4.3.5.2 South Africa Myasthenia Gravis Treatment Market by Type
      • 6.4.3.6 Nigeria Myasthenia Gravis Treatment Market
        • 6.4.3.6.1 Nigeria Myasthenia Gravis Treatment Market by End-use
        • 6.4.3.6.2 Nigeria Myasthenia Gravis Treatment Market by Type
      • 6.4.3.7 Rest of LAMEA Myasthenia Gravis Treatment Market
        • 6.4.3.7.1 Rest of LAMEA Myasthenia Gravis Treatment Market by End-use
        • 6.4.3.7.2 Rest of LAMEA Myasthenia Gravis Treatment Market by Type

Chapter 7. Company Profiles

  • 7.1 AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Regional Analysis
    • 7.1.4 Research & Development Expenses
    • 7.1.5 Recent strategies and developments:
      • 7.1.5.1 Approval and Trails:
    • 7.1.6 SWOT Analysis
  • 7.2 Octapharma AG
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Research & Development Expenses
  • 7.3 Novartis AG
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expense
    • 7.3.5 SWOT Analysis
  • 7.4 Pfizer, Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Regional & Segmental Analysis
    • 7.4.4 Research & Development Expense
    • 7.4.5 Recent strategies and developments:
      • 7.4.5.1 Approval and Trails:
    • 7.4.6 SWOT Analysis
  • 7.5 Allergan PLC (AbbVie, Inc.)
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Regional Analysis
    • 7.5.1 Research & Development Expense
    • 7.5.2 SWOT Analysis
  • 7.6 F. Hoffmann-La Roche Ltd.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Segmental and Regional Analysis
    • 7.6.4 Research & Development Expense
    • 7.6.5 SWOT Analysis
  • 7.7 GlaxoSmithKline PLC (GSK)
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Regional Analysis
    • 7.7.4 Research & Development Expense
    • 7.7.5 SWOT Analysis
  • 7.8 Bausch Health Companies Inc
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expenses
    • 7.8.5 SWOT Analysis
  • 7.9 Kedrion S.p.A
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Research & Development Expenses
    • 7.9.4 SWOT Analysis
  • 7.10. Zydus Lifesciences Ltd.
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Segmental and Regional Analysis
    • 7.10.4 Research & Development Expense
    • 7.10.5 SWOT Analysis

Chapter 8. Winning imperatives of Myasthenia Gravis Treatment Market